NYC Early Cancer Detection Blood Test At Home :leaa
call leaa

NYC Early Cancer Detection
Blood Test At Home

The test can detect 50 types of cancers through
a simple blood draw, giving you the power of early detection
to proactively protect your health, and much of the time, can detect cancer
before anyone starts showing symptoms

"There is a lot to live for"

whois it for?

This test is explicitly aimed at patients 50 or older or those who are at higher risk of cancer.

The benefits you get with this test is that it tests for 50 types of cancers through a simple blood draw. and with leaa, you get it done in the comfort and privacy of your home.

On the other hand, Colorectal cancer is usually thought of as an older adult’s disease. But it’s claiming the lives of more and more young men in their 40’s, 30’s, and even 20’s

This test is a modern marvel of medicine — and can recognize cancers that are more difficult to diagnose at a decisive junction, like blood cancers, ovarian cancer, pancreatic cancer, breast cancer, and more.





















A breakthrough innovation for early cancer detection

The test uses next-generation sequencing (NGS) and machine-learning
algorithms to analyze methylation patterns of cell-free DNA (cfDNA)
in the bloodstream.

All cells — cancer and non-cancer — shed DNA into the bloodstream.
cfDNA can carry cancer-specific information in its methylation patterns.
DNA methylation is a process used by cells to regulate gene expression.









































results in 10 business days

The test detects abnormalities in the methylation patterns of cell-free
DNA (cfDNA) that could indicate the presence of cancer.

When a cancer signal is detected, the test identifies the signal's
origin with high accuracy to help guide the following steps to diagnosis.
Test results should be available to the ordering healthcare provider
within ten business days from when the sample arrives at the lab.

Price is $1699, all included
With the doctor's home visit and lab fees.
Same day responce


Book a home Blood test for 
early cancer detection, the test can detect over 50 types of cancers through a simple blood draw. 

This test is not covered by insurance
The test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. It is intended to be used in addition to and not replace other cancer screening tests your healthcare provider recommends.

After you try leaa once 
you will never go back to waiting in line again



50 Types of cancer detected

a
Adrenal Cortical Carcinoma Ampulla of Vater
Anus
Appendix Carcinoma
b
Bone Breast
c
Cervix Uteri
Colon and Rectum
Corpus Uteri Carcinoma and Carcinosarcoma
Corpus Uteri Sarcoma
d
Distal Bile Duct
e
Esophagus and Esophagogastric Junction Exocrine Pancreas
g
Intrahepatic Bile Ducts

k
Kidney
l
Larynx Leukemia Liver Lung
m
Malignant Pleural Mesothelioma Melanoma of the Skin
Merkel Cell Carcinoma
n
Nasal Cavity and Paranasal Sinuses Nasopharynx
Neuroendocrine Tumors of the Appendix Neuroendocrine Tumors of the
Colon and Rectum
Neuroendocrine Tumors of the Pancreas
0
Oral Cavity
Oropharynx (p16-) and Hypopharynx
Ovary, Fallopian Tube and Primary Peritoneal Carcinoma
Penis
Perihilar Ducts
Plasma Cell Myeloma and Plasma Cell Disorders
Prostate

r
Renal Pelvis and Ureter
s
Small Intestine
Soft Tissue Sarcoma of the Abdomen and Thoracic
Visceral Organs
Soft Tissue Sarcoma of the Head and Neck
Soft Tissue Sarcoma of the Retroperitoneum
Soft Tissue Sarcoma of the Trunk and Extremities
Soft Tissue Sarcoma Unusual Histologies and Sites
Stomach
t
Testis
u
Urinary Bladder
v
Vagina Vulva
Gallbladder
Gastrointestinal Stromal Tumor Gestational Trophoblastic Neoplasms
h
Hodgkin and Non-Hodgkin Lymphoma HPV-Mediated (p16+) Oropharyngeal

In the event that a diagnostic evaluation after a ​"Cancer Signal Detected"
result with the test does not confirm cancer, patients may be eligible
for a complimentary retest.

The request for a retest must be placed by the leaa's healthcare provider
managing the patient's diagnostic evaluation.
The retest must be administered within 3 – 6 months after the initial test.
To initiate a request for a retest, contact leaa.

results in 10 business days

The test detects abnormalities in the methylation patterns of cell-free
DNA (cfDNA) that could indicate the presence of cancer.
When a cancer signal is detected, the test identifies the signal's
origin with high accuracy to help guide the following steps to diagnosis.
Test results should be available to the ordering healthcare provider
within ten business days from when the sample arrives at the lab.

Cancer cases enrolled in CCGA Study were assigned a “cancer type” as defined in the American Joint Committee on Cancer (AJCC) manual (8th edition). Cancer signal was detected across more than 50 AJCC-cancer types, which supports the potential for the test to detect cancer signal over a diverse range of cancers across a wide biologic spectrum.

Important Safety Information
The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. is intended to detect cancer signals and predict where in the body the cancer signal is located. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “cancer signal not detected” does not rule out cancer. A test result of “cancer signal detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur.

Rx only.
clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The test was developed, and its performance characteristics were determined by GRAIL. The test has not been cleared or approved by the Food and Drug Administration. clinical laboratory is regulated under CLIA to perform high-complexity testing. The test is intended for clinical purposes.

The test can be included in leaa's home doctor
visit with our healthcare provider through a simple blood draw.

call leaa

contact

866 275 7594
Email: support@Leaa.io
Sun - Fri
7:00am -11:00pm

HQ

510 FIFTH AVE NYC
& 195 BROADWAY
THIRD FLOOR


IV Drip

NAD IV 
Hangover IV
Skin Whitening IV 
IV Therapy  
Vitamin C IV
R Blend
M Blend


Terms

Terms
Policy
Hipaa
Accessibility



Medical Providers On Demand Home Visits LEAA LLC EST 2017© Copyright
The Content On This Website Is Copyright Protected All Rights Reserved. 

ALLURE